Mildly dilated cardiomyopathy (MDCM) has been proposed as a subtype of dilated cardiomyopathy (DCM) characterized by systolic dysfunction in the absence of significant LV dilatation. Few data on the characteristics and outcomes of MDCM patients are available. We sought to assess the main features and the long-term natural history of MDCM. 
Introduction
Idiopathic dilated cardiomyopathy (DCM) is a heterogeneous primary myocardial disease frequently genetically based, with a variable clinical presentation and natural history affecting young individuals with a potential long life expectancy. Although recent advances in heart failure (HF) management dramatically improved the prognosis of DCM, it remains a frequent cause of HF and one of the main causes of heart transplantation (HTx).
1,2
Left ventricular remodelling is known to be associated with a poor outcome in patients with DCM. 3 However, an initial presentation with significant LV dysfunction without LV remodelling is not uncommon. A new category defined as hypokinetic non-dilated cardiomyopathy has indeed recently been included in the proposal for an updated definition of DCM. 4 Actually, mildly dilated cardiomyopathy (MDCM) was first reported almost three decades ago as a disease with similar features to DCM despite a not or mildly dilated left ventricle.
Therefore, the aims of the present study were: (i) to identify the extent of MDCM presentation in a large cohort of patients with DCM; and (ii) to investigate the impact of MDCM at the time of first evaluation on long-term evolution and prognosis.
Methods

Study population and study design
All the DCM patients consecutively enrolled in the Heart Muscle Disease Registry of Trieste 2 from 1 January 1988 to 31 December 2010 and with an LVEF <45% were considered eligible for the present study and retrospectively analysed. A total of 16 patients with no available LVEF and/or LV end-diastolic volume index (LVEDVI) quantification owing to poor quality imaging were excluded.
The diagnosis of DCM was determined according to the World Health Organization criteria. 1, 9 Ischaemic aetiology was excluded with coronary angiography, systematically performed in patients ≥35 years, with cardiovascular risk factors, and/or without a family history of DCM. Patients with clinical suspicion of active myocarditis (i.e. recent-onset HF without severe LV remodelling, suspected clinical features) underwent endomyocardial biopsy. Patients with significant CAD (>50% stenosis of a major coronary artery), history of severe systemic hypertension (>160/100 mmHg), biopsy-proven active myocarditis, alcohol intake >100 g/day, significant organic valve disease, tachycardia-induced cardiomyopathy, peripartum cardiomyopathy, congenital heart disease, or advanced systemic disease affecting short-term prognosis were excluded. 2 Family history was strictly investigated and all familial cases fulfilled the published criteria.
10 At the time of enrolment, each patient underwent detailed clinical evaluation, 12-lead ECG, transthoracic echocardiography, and 24-h Holter monitoring.
The condition of MDCM was defined by LVEF <45% and a normal or mildly dilated left ventricle. The threshold for mildly increased LV dimension was established according to the international recommendations for echocardiographic LV quantification: 11 LVEDVI ≤89 mL/m 2 in males and ≤70 mL/m 2 in females. The remaining patients were classified as DCM.
Evolution from MDCM to DCM was systematically re-evaluated at each available follow-up. By protocol, all patients underwent a structured follow-up (clinical and echocardiographic) 6, 12, and 24 months after enrolment and then every 2 years. Non-sustained ventricular tachycardia (NSVT) on Holter was defined as ≥3 consecutive ventricular premature beats at ≥120 b.p.m.
After enrolment, if not contraindicated, all patients received ACE inhibitors/ARBs and beta-blockers titrated to the highest tolerated dose. Moreover, from 1998 onward, implantable cardioverter defibrillator (ICD) therapy was introduced for primary prevention of sudden cardiac death in high-risk patients (persistent LVEF ≤35% and NYHA functional class II-III despite optimal medical therapy). 12 Since 2005 patients with conventional indications (LVEF ≤35%, QRS >120 ms, and complete LBBB) were treated with CRT.
12
The primary study outcome measure was a composite of all-cause mortality and heart transplantation (D/HTx). The follow-up ended on 31 December 2014, or at the date of D/HTx; thus, each patient had a potential follow-up ≥48 months. Information regarding the primary endpoint was available for all the study patients. Information regarding the endpoints was obtained from the patients, their physician, or the registers of death of the municipalities of residence. The institutional ethical board approved the study, and informed consent was 
Echocardiographic study
Left ventricular dimensions, systolic and diastolic function were assessed according to international guidelines. 11, 13 Specifically, LV volumes and LVEF were calculated by Simpson's biplane method. All volumes were indexed according to body surface area. Transmitral E and A wave velocities were measured using pulsed wave Doppler at the level of the mitral leaflet tips. The LV filling pattern was classified as restrictive (RFP) in the presence of E-wave deceleration time <120 ms or E/A ≥2 associated with E-wave deceleration time ≤150 ms. 13 Right ventricular dysfunction was defined by a right ventricular fractional area change <35%. 11 Mitral regurgitation (MR) was assessed using a multiparametric approach, by measuring the vena contracta width at colour-flow Doppler or, whenever feasible, the effective regurgitant volume or orifice area (EROA) measured by the proximal isovelocity surface area (PISA), and graded on a three-point scale according to current recommendations. 14 All measurements were obtained from the mean of three beats (patients in sinus rhythm) or of five beats (AF).
Statistical analysis
Summary statistics of clinical and instrumental variables were expressed as the mean and standard deviation, median and interquartile range, or counts and percentage, as appropriate. Comparisons between groups at baseline and at different follow-up visits were made by the analysis of variance (ANOVA) test on continuous variables, using the Brown-Forsythe statistic when the assumption of equal variances did not hold, or by the non-parametric median test when necessary; the 2 test was calculated for discrete variables. To assess the longitudinal evolution of the parameters under study, two analyses were run: first, separately in each follow-up, standard tests were calculated ( 2 test for binary parameters and the ANOVA test for the continuous parameters). Secondly, linear mixed-effects models with 'time' (= follow up) and 'group' as covariates ('group': MDCM vs. DCM) and the interaction term 'time' × 'group' were estimated, in order to investigate if a different time behaviour was present between groups. For the binary parameters, generalized linear mixed models were applied, with the same covariates. 15 Uni-and multivariable logistic regression was used in the MDCM group to find factors associated with evolution into DCM.
We also performed a stepwise Cox regression in order to find the subset of the most influential predictors for D/HTx in the persistent MDCM group, starting from the list of significant and clinically relevant parameters which emerged at univariable analysis. A time-dependent receiver operating characteristic (ROC) curve was then estimated in order to evaluate the prognostic accuracy of the Cox model by using the R library 'timeROC' with an events-horizon fixed at 96 months-corresponding to the follow-up time with 75% of events in the group of interest. The general survival curves for D/HTx were calculated by the Kaplan-Meier method, and the log-rank test was used to assess differences between groups. Results are regarded as statistically significant when P < 0.05. All calculations were performed by using IBM SPSS version 19.0 for Windows and the R statistical software version 3.02, packages 'lme4' and 'nlme'. 
Results
The study population comprised 638 patients. Median follow-up was 131 (78-201) months. According to the above-mentioned criteria, 226 (35%) were classified as MDCM. As shown in Figure 1 , the number of MDCM cases significantly increased over time (P < 0.001). At baseline, compared with DCM patients, MDCM cases were more frequently asymptomatic, with a higher LVEF, a smaller left atrial area, and a lower rate of LBBB and RFP. Concerning medical treatment, only 18% and 46% of the whole population was treated with beta-blockers and ACE inhibitors, respectively, at the time of referral, mostly at suboptimal dosages. After the first evaluation, the majority of patients started the recommended therapy according to current evidence with no differences in administration of beta-blockers and ACE inhibitors/ARBs between the two groups. The rate of ICD use was similar over the follow-up, while CRT was less frequent in MDCM patients ( Table 1) . Figure 2 and Table 2 show the longitudinal trends of the main clinical and echocardiographic features over time. After an initial improvement in symptoms, both MDCM and DCM patients gradually and progressively worsened in terms of NYHA functional class in the long term. LVEF strongly improved at the 6-month re-evaluation in both the subgroups, then gradually decreased in MDCM patients, whereas there was a trend in improvement in DCMs. On the other hand, RFP decreased early in both the subgroups, with a similar prevalence thereafter. A significant reduction in LV dimensions was observed at first re-evaluation only in DCM cases, although they were persistently more dilated compared with MDCM. The linear mixed-effect models confirmed these observations. . Interestingly, throughout the follow-up, 55 MDCM patients (24%) evolved to DCM by an increase in the LVEDVI beyond the pre-defined cut-off. The shift to DCM conditions largely occurred in the first 2 years (36, 58, and 69% at 6, 12, and 24 month follow-up, respectively). The main characteristics of this subgroup at enrolment, compared with patients with persistent MDCM, are shown in Table 3 . At logistic regression analysis, no baseline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (n = 103)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . variables were found to be independently associated with subsequent evolution in DCM. Furthermore, a significant deterioration of symptoms was also not observed. Indeed, only 6/55 patients (11%) had concomitant worsening of NYHA class at the time of evolution from MDCM to DCM.
Temporal trends of the main clinical and echocardiographic characteristics
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Long-term outcomes
During the study period, 209 patients (33%) died (n = 144) or underwent HTx (n = 65). Kaplan-Meier survival curves are presented in Figure 3A . Globally, MDCM patients had better survival rates as compared with DCM patients (D/HTx at 10 years 15% vs. 30% in MDCM and DCM, respectively; P < 0.001).
It is noteworthy that patients with baseline MDCM features but subsequently evolving into DCM carried a consistent progressively worsening prognosis that became similar to that of DCM patients in the very long-term follow-up ( Figure 3B ; P = 0.200).
High-risk mildly dilated cardiomyopathy patients
Finally, uni-and multivariable Cox regression analysis for D/HTx was performed in order to identify patients at higher risk in the persistent MDCM subgroup (n = 171) ( Survival curves were estimated according to the presence of one or both of the two risk factors which emerged at multivariate analysis ( Figure 3C ). Of note, overall survival greatly declined from the time of enrolment in patients with both RFP and NSVT, with a rate of D/HTx close to 50% at 5 years (P < 0.001 vs. patients with no RFP/NSVT; P = 0.001 vs. patients with one of RFP or NSVT), whereas patients carrying only one risk factor showed an intermediate prognosis (P = 0.016 vs. patients with no RFP/NSVT).
Discussion
Main findings
In the present analysis including a large cohort of DCM patients with significant LV systolic dysfunction, more than one-third fulfilled the criteria for MDCM at enrolment. The main characteristics at baseline indicated that a large part of MDCMs were actually 'conventional' DCM diagnosed at a less advanced stage, thereby presenting a better long-term prognosis. In fact, most of the differences observed at first evaluation progressively became less evident, with a similar clinical and echocardiographic evolution of the two subgroups throughout the follow-up. optimal medical treatment, with HTx-free survival approaching that of patients with features of 'conventional' DCM. Finally, among the subgroup of persistent MDCM patients, those presenting with severe diastolic dysfunction and non-sustained ventricular arrhythmias showed a very poor outcome. As far as we are aware, this is the first study that specifically investigated the natural history and the long-term prognosis of MDCM in a large and well-characterized cohort of DCM patients.
Characterization and long-term natural history of mildly dilated cardiomyopathy
Although the hypokinetic non-DCM category has recently been introduced in the revised classification of DCM, 4 only a few older studies on MDCM are available, lacking a univocal definition of the disease and including small samples followed for a short period and frequently undertreated.
5 -7,16 Doumas et al. recently reported a low rate of the non-dilated condition among patients with non-ischaemic systolic LV dysfunction, mainly in hypertensive cardiomyopathies with LV hypertrophy and AF. 8 However, despite the same LVEF cut-off for inclusion, our subjects were younger, with fewer co-morbidities and all affected by idiopathic DCM, while patients with a history of systemic hypertension have been systematically excluded.
In our series, MDCM patients were characterized by a shorter duration of symptoms and a less advanced NYHA functional class as compared with DCM patients, suggesting an earlier diagnosis probably supported by the structured family screening regularly performed in our centre.
17 Accordingly, the proportion of those with MDCM over the years progressively increased in parallel with the more extensive application of family screening protocols ( Figure 1) .
As previously reported, LV reverse remodelling in response to HF medical strategies exerts a positive effect on the outcome of patients affected by DCM. 18 Nevertheless, the evolution of MDCM over time in terms of symptoms, as well as in the main echocardiographic markers of disease, is largely unknown. In our series, MDCM patients initially improved their symptoms but then gradually worsened during long-term follow-up, thereby following the natural course of DCM. Similarly, in both subgroups, LV systolic function greatly increased in the first period after enrolment, but those with MDCM experienced an increasing worsening rate compared with those with DCM afterwards.
Of note, one-fifth of MDCM patients gradually evolved into DCM during the follow-up. This mainly occurred during the first 2 years of follow-up. Interestingly, the observed rate of D/HTx concomitantly increased among these patients, progressively approaching that of DCM. Unfortunately, we could not identify baseline predictors of subsequent evolution, and no concomitant changes in symptoms were observed in most of the patients shifting to DCM. Other tools such as cardiac magnetic resonance might be helpful to better understand which patients are more prone to an unfavourable progression.
Finally, consistently with the features of a less advanced disease, most of the patients with persistent MDCM showed a favourable long-term prognosis. As previously reported, the advances in diagnostic and therapeutic strategies led in the last decades to a dramatic improvement of the long-term outcome of patients with DCM. 2 This cannot be considered only the result of different treatments, but also the effect of a more systematic and accurate approach, whereby young patients present with clues of an underlying cardiac disease.
High-risk persistent cases of mildly dilated cardiomyopathy
The identification of patients at high risk of adverse outcome within the apparent benign population of persistent MDCMs is perhaps one of the most interesting findings of this study. In fact, although the persistent MDCM condition globally carried a lower risk of events, a high mortality rate was observed in the subgroup of patients presenting with RFP and NSVT at first evaluation. Interestingly, in this subset, LVEF was not independently predictive of survival. We hypothesize that in patients with persistent MDCM, the presence of severe diastolic dysfunction and non-sustained ventricular arrhythmias might hide distinctive genotypes with a less favourable course. For instance, within the broad spectrum of genes involved in DCM, lamin A/C mutations have been associated with hypo-and hyperkinetic arrhythmias and convey an increased risk of sudden cardiac death independent of the degree of systolic dysfunction and LV dilatation. 19 On the other hand, a 'restrictive' phenotype has been included in the clinical spectrum of desmin-related cardiomyopathies, and desmin abnormalities were correlated with progressive diastolic dysfunction in patients with idiopathic DCM. 20 23 Furthermore, additional information from other techniques such as tissue characterization by cardiac magnetic resonance could be helpful to clarify further the real pathological substrate of the MDCM condition.
Study limitations
Several limitations need to be acknowledged. As in all observational studies on long-term registries, this study suffers from the common bias due to its retrospective design. The study population was enrolled in a tertiary referral centre for cardiomyopathies and HF, thus imposing a selection bias with respect to the characteristics of DCM in the general population.
Information from cardiac magnetic resonance and genetic testing was not systematically available because these tests were performed in a minority of selected cases. These aspects will need to be assessed in future dedicated prospective investigations.
Definite diagnostic criteria for MDCM were not univocally defined in previous studies.
1,5 -8,16 Z-scores have been recently suggested as the preferred method for the assessment of LV dilatation, and hypokinetic non-DCM was defined by reduced LVEF without dilatation. 4 Since Z-scores are poorly validated in adults, 24 in the present study we decided to consider LV volumes, according to the recently upgraded recommendations for echocardiographic chamber quantification, 11 then including in the MDCM group patients with normal LV dimensions or mild LV dilatation as the majority of the previously published studies. We acknowledge the limitations related to this arbitrary decision and the lack of consensus surrounding this specific clinical entity. However, for all the reasons above, we believe that including patients with no or even slight LV dilatation and defining them as MDCM might be the most correct choice with the current state of knowledge. Furthermore, to limit the potential bias due to the inclusion of patients with borderline LV systolic dysfunction (i.e. LVEF interval 45-50%) and according to the recently proposed definitions, 4 we chose an LVEF <45% threshold for inclusion in our analysis.
Conclusions
The majority of MDCM patients share the features of less advanced DCM, being consistently characterized by a better long-term survival. However, a non-negligible number of MDCM patients presented a less favourable progression that parallels that of typical DCM in the long term, further attesting to the importance of a careful management despite the apparently more benign condition. Finally, RFP and NSVT emerged as potentially useful high-risk indicators that might improve the prognostic stratification of patients with persistent MDCM. Future studies will investigate whether specific genetic defects might account for these more hazardous phenotypes of MDCM. Conflict of interest: none declared.
